State Street Corp Outlook Therapeutics, Inc. Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.22 - $0.66 $8,078 - $24,236	36,722 Added 1.32%	2,826,493 $1.1 Million
Q3 2023 Nov 14, 2023	BUY	$0.2 - $1.78 $7,558 - $67,273	37,794 Added 1.37%	2,789,771 $613,000
Q2 2023 Aug 14, 2023	BUY	$1.02 - $1.89 $746,563 - $1.38 Million	731,925 Added 36.23%	2,751,977 $4.79 Million
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $100,363 - $135,490	100,363 Added 5.23%	2,020,052 $2.2 Million
Q4 2022 Feb 14, 2023	SELL	$0.87 - $1.33 $25,560 - $39,075	-29,380 Reduced 1.51%	1,919,689 $2.07 Million
Q3 2022 Nov 15, 2022	BUY	$1.02 - $1.26 $60,924 - $75,259	59,730 Added 3.16%	1,949,069 $2.38 Million
Q2 2022 Aug 15, 2022	BUY	$0.91 - $2.01 $202,265 - $446,762	222,270 Added 13.33%	1,889,339 $1.93 Million
Q1 2022 May 16, 2022	BUY	$1.22 - $2.03 $121,160 - $201,603	99,312 Added 6.33%	1,667,069 $2.97 Million
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $3,907 - $6,861	3,077 Added 0.2%	1,567,757 $2.13 Million
Q3 2021 Nov 15, 2021	BUY	$2.12 - $2.76 $470,991 - $613,178	222,166 Added 16.55%	1,564,680 $3.4 Million
Q2 2021 Aug 16, 2021	BUY	$1.78 - $2.76 $2.39 Million - $3.71 Million	1,342,514 New	1,342,514 $3.34 Million

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.18B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.